Navigation Links
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer

Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.

Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer. The companies also confirmed that they are planning a company- sponsored Phase 3 study of Nexavar in the adjuvant treatment of HCC following the complete removal of early stage liver cancer.

The sNDA submission is based on positive data from the international, Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial which demonstrated that Nexavar extended overall survival by 44 percent in patients with HCC (HR=0.69; p=0.0006) versus placebo.

There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups with the most commonly observed adverse events in patients receiving Nexavar being diarrhea and hand-foot skin reaction. Currently, there are no FDA-approved drug therapies that significantly extend survival of patients with liver cancer.

"These results are particularly meaningful considering that death rates from liver cancer continue to increase," said Susan Kelley, M.D., vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "After more than 100 clinical studies of many agents over three decades.

Nexavar is the first drug therapy to demonstrate a significant survival benefit for patients with HCC, and, if approved, may fulfill a serious unmet need with a manageable toxicity profile."

HCC, the most common form of liver cancer, is responsible for about 90 percent of the primary liver cancers in adults. It is the fifth
'"/>




Page: 1 2

Related medicine news :

1. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
2. Bayer Wins Positive Response For Marketing Its Cancer Drug
3. Genomatix Licensed By Bayer Healthcare
4. Bayer to Market Biocon Insulin in China
5. Test for Esophageal Reflux Licensed to Bayer by University
6. Recd Number of Abstracts Submitted for Sci Cong on Osteoporosis
7. MBBS Aspirants Get 90 Days To Submit Caste Validity Certificate
8. New Drug Application Submitted for Investigational Antibiotic Doripenem
9. New Supplemental Therapy for Common Jaw Disorder
10. Prostate Cancer Can Be Treated By Application Of LASER Technology
11. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
Post Your Comments:
(Date:10/19/2014)... 2014 Recently, BambooIndustry.com, one of the ... new range of bamboo deckings . Moreover, the ... items; they are now available at deeply discounted rates. ... is hard to overstate the significance of online business ... online services. The company’s workers are striving to deliver ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, ... and announced that JustHost, GoDaddy and HostMonster are ... market. VPS (Virtual Private Server) is the method ... servers, each of which has the appearance and ... That is why the site pays close attention ...
(Date:10/19/2014)... October 20, 2014 Stephen T. Greenberg, M.D., ... nominated for the 10th consecutive year as one of Long ... Greenberg was also been nominated as the best provider for ... nominated as best Day Spa and best Laser Treatment center ... 14th and readers can vote for the contest once per ...
(Date:10/19/2014)... 2014 The federal litigation involving ... move forward in Massachusetts federal court, where more ... the dialysis medication, Bernstein Liebhard LLP reports. ... shows 2,127 claims now filed over GranuFlo and ... U.S. District Court, District of Massachusetts. Plaintiffs in ...
(Date:10/19/2014)... October 19, 2014 When patients and their ... Hospital and turn the corner to face the Hummingbird Gift ... hospital volunteers to sell there. There’s unique home décor. Cooking ... so obvious, though, is the importance this small gift shop ... Tappahannock and Northern Neck community of the future. , ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Riverside Tappahannock Hospital Capital Campaign Gets Boost From Community Through Gift Shop 2Health News:Riverside Tappahannock Hospital Capital Campaign Gets Boost From Community Through Gift Shop 3
... Given Green Light by Insurers, SANTA MONICA, ... California health regulators acknowledged that patients,should be able ... their health coverage. Yet the details of the ... insurers, said Consumer Watchdog,allowing them in many cases ...
... aciclovir shows no added benefit , , THURSDAY, June 19 ... reduce the risk of HIV-1 infection in people who ... U.S. study finds. , Previous research has shown that ... common cause of genital herpes -- increases the risk ...
... Visit redcrossracing.com, WASHINGTON, June 19 3M Company ... recently devastated,by severe weather in the Midwest. For the ... and toll-free number, 1-800-RED-CROSS, will be,displayed on the TV ... also donated,approximately 25,000 units of hand sanitizer, insect repellant ...
... Ind., June 19 Zimmer Holdings, Inc.,(NYSE: ... that it will partner with AmeriCares,one of ... donations, to support emergency response and ongoing ... at $1 million to,three of AmeriCares, primary ...
... lead to more effective treatments for diarrhea worldwide, study says ... they,ve identified an enzyme that may help dysentery-causing amoeba evade ... lead to new ways to fight dysentery, a form of ... and is a serious health threat in many regions. ...
... Center,is pleased to announce that KARE 11 TV has ... Distinction., Over the years, Twin Cities based KARE ... 264 (275 including 2008) community,volunteers. The story of each ... Courage Center volunteers (including three pairs of,volunteers) have been ...
Cached Medicine News:Health News:PacifiCare 'Rescission' Settlement Gives Lip Service to Patient Losses But Stacks Legal Deck in Favor of Insurers 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:3M Company Supports Red Cross Relief Efforts through Red Cross Racing 2Health News:3M Company Supports Red Cross Relief Efforts through Red Cross Racing 3Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 2Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 3Health News:Scientists ID Enzyme That Allows Dysentery Amoeba to Hide 2Health News:Courage Center Honored With KARE TV's 2008 Eleven Who Care Agency of Distinction 2
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
(Date:10/17/2014)... ANGELES , Oct. 17, 2014 CytRx ... and development company specializing in oncology, announced that data ... aldoxorubicin for the treatment of first-line soft tissue sarcoma ... at the 2014 Connective Tissue Oncology Society (CTOS) Annual ... Berlin , Germany. Due to the longer ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6
... Inc. (OTC Bulletin Board: MCLN ), the leading ... and disposal of medical waste and the destruction of ... the 2010 second quarter for the period ended June 30, ... MedClean has addressed its capital requirements ...
... Group, Inc., (EHG), parent company of DentalXChange, a ... solutions for patients, payers and providers in the ... has selected DentalXChange as its latest Endorsed Program. ... members to receive an immediate savings on DentalXChange,s ...
Cached Medicine Technology:MedClean Technologies Announces Second Quarter Results 2MedClean Technologies Announces Second Quarter Results 3MedClean Technologies Announces Second Quarter Results 4MedClean Technologies Announces Second Quarter Results 5DentalXChange Endorsed by California Dental Association 2DentalXChange Endorsed by California Dental Association 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: